# Isatuximab With or Without Lenalidomide in Patients With High Risk Smoldering Multiple Myeloma (ISAMAR)

> **NCT02960555** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 61 (estimated)

## Conditions studied

- Smoldering Plasma Cell Myeloma

## Interventions

- **BIOLOGICAL:** Isatuximab
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT02960555
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-02-08
- **Primary completion:** 2027-04-30
- **Final completion:** 2030-04-30
- **Target enrollment:** 61 (ESTIMATED)
- **Last updated:** 2026-04-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02960555

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02960555, "Isatuximab With or Without Lenalidomide in Patients With High Risk Smoldering Multiple Myeloma (ISAMAR)". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT02960555. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*